Edwards' heart valve boosted by trials
This article was originally published in Clinica
Results of two studies have backed Edwards Lifesciences' Sapien transcatheter heart valve, when delivered with the Ascendra transapical delivery system. Interim results from 67 patients in the PARTNER EU registry showed a 30-day survival rate of 82%, and a six-month survival rate of 56%. Furthermore, results from a post-marketing registry, SOURCE, showed a 30-day survival rate of 88% in the 309 cases evaluated. The data were presented at the annual meeting of the European Association for Cardio-Thoracic Surgery, held in Lisbon, Portugal in early September.